Asymmetrical effect of levodopa on the neural activity of motor regions in PD.
Identifieur interne : 000789 ( PubMed/Checkpoint ); précédent : 000788; suivant : 000790Asymmetrical effect of levodopa on the neural activity of motor regions in PD.
Auteurs : Kristina Martinu [Canada] ; Atsuko Nagano-Saito [Canada] ; Stuart Fogel [Canada] ; Oury Monchi [Canada]Source :
- PloS one [ 1932-6203 ] ; 2014.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Brain Mapping, Cerebellum (drug effects), Cerebellum (pathology), Cerebellum (physiopathology), Female, Hand (pathology), Humans, Levodopa (pharmacology), Levodopa (therapeutic use), Magnetic Resonance Imaging, Male, Middle Aged, Movement (drug effects), Parkinson Disease (drug therapy), Parkinson Disease (pathology), Parkinson Disease (physiopathology).
- MESH :
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug effects : Cerebellum, Movement.
- drug therapy : Parkinson Disease.
- pathology : Cerebellum, Hand, Parkinson Disease.
- physiopathology : Cerebellum, Parkinson Disease.
- Aged, Brain Mapping, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged.
Abstract
Parkinson's disease (PD) is a neurodegenerative illness often characterized by asymmetrical symptoms. However, the reason for this asymmetry and the cerebral correlates underlying symptom asymmetry are still not well understood. Furthermore, the effects of levodopa on the cerebral correlates of disease asymmetry have not been investigated. In this study, right-handed PD patients performed self-initiated, externally triggered and repetitive control finger movements with both their right and left hands during functional magnetic resonance imaging (fMRI) to investigate asymmetrical effects of levodopa on the hemodynamic correlates of finger movements. Patients completed two experimental sessions OFF and ON medication after a minimum of 12 hours medication withdrawal. We compared the effect of levodopa on the neural activation patterns underlying the execution of both the more affected and less affected hand for self-initiated and externally triggered movements. Our results show that levodopa led to larger differences in cerebral activity for movements of the more affected, left side: there were significant differences in activity after levodopa administration in regions of the motor cortico-striatal network when patients performed self-initiated and externally triggered movements with their left hand. By contrast, when patients used their right hand, levodopa led to differences in cerebellar activity only. As our patients were affected more severely on their left side, we propose that levodopa may help provide additional dopaminergic input, improving movements for the more severely affected side. These results suggest that the impact of reduced dopamine in the cortico-striatal system and the action of levodopa is not symmetrical.
DOI: 10.1371/journal.pone.0111600
PubMed: 25369523
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25369523Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Asymmetrical effect of levodopa on the neural activity of motor regions in PD.</title><author><name sortKey="Martinu, Kristina" sort="Martinu, Kristina" uniqKey="Martinu K" first="Kristina" last="Martinu">Kristina Martinu</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Nagano Saito, Atsuko" sort="Nagano Saito, Atsuko" uniqKey="Nagano Saito A" first="Atsuko" last="Nagano-Saito">Atsuko Nagano-Saito</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Fogel, Stuart" sort="Fogel, Stuart" uniqKey="Fogel S" first="Stuart" last="Fogel">Stuart Fogel</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada; Brain & Mind Institute, Department of Psychology, Western University, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada; Brain & Mind Institute, Department of Psychology, Western University, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Monchi, Oury" sort="Monchi, Oury" uniqKey="Monchi O" first="Oury" last="Monchi">Oury Monchi</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada; Department of Radiology, Université de Montréal, Montreal, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada; Department of Radiology, Université de Montréal, Montreal, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25369523</idno><idno type="pmid">25369523</idno><idno type="doi">10.1371/journal.pone.0111600</idno><idno type="wicri:Area/PubMed/Corpus">000641</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000641</idno><idno type="wicri:Area/PubMed/Curation">000641</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000641</idno><idno type="wicri:Area/PubMed/Checkpoint">000641</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000641</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Asymmetrical effect of levodopa on the neural activity of motor regions in PD.</title><author><name sortKey="Martinu, Kristina" sort="Martinu, Kristina" uniqKey="Martinu K" first="Kristina" last="Martinu">Kristina Martinu</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Nagano Saito, Atsuko" sort="Nagano Saito, Atsuko" uniqKey="Nagano Saito A" first="Atsuko" last="Nagano-Saito">Atsuko Nagano-Saito</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Fogel, Stuart" sort="Fogel, Stuart" uniqKey="Fogel S" first="Stuart" last="Fogel">Stuart Fogel</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada; Brain & Mind Institute, Department of Psychology, Western University, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada; Brain & Mind Institute, Department of Psychology, Western University, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Monchi, Oury" sort="Monchi, Oury" uniqKey="Monchi O" first="Oury" last="Monchi">Oury Monchi</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada; Department of Radiology, Université de Montréal, Montreal, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada; Department of Radiology, Université de Montréal, Montreal, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (pharmacology)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Brain Mapping</term><term>Cerebellum (drug effects)</term><term>Cerebellum (pathology)</term><term>Cerebellum (physiopathology)</term><term>Female</term><term>Hand (pathology)</term><term>Humans</term><term>Levodopa (pharmacology)</term><term>Levodopa (therapeutic use)</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term><term>Movement (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (pathology)</term><term>Parkinson Disease (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cerebellum</term><term>Movement</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Cerebellum</term><term>Hand</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Cerebellum</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Brain Mapping</term><term>Female</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is a neurodegenerative illness often characterized by asymmetrical symptoms. However, the reason for this asymmetry and the cerebral correlates underlying symptom asymmetry are still not well understood. Furthermore, the effects of levodopa on the cerebral correlates of disease asymmetry have not been investigated. In this study, right-handed PD patients performed self-initiated, externally triggered and repetitive control finger movements with both their right and left hands during functional magnetic resonance imaging (fMRI) to investigate asymmetrical effects of levodopa on the hemodynamic correlates of finger movements. Patients completed two experimental sessions OFF and ON medication after a minimum of 12 hours medication withdrawal. We compared the effect of levodopa on the neural activation patterns underlying the execution of both the more affected and less affected hand for self-initiated and externally triggered movements. Our results show that levodopa led to larger differences in cerebral activity for movements of the more affected, left side: there were significant differences in activity after levodopa administration in regions of the motor cortico-striatal network when patients performed self-initiated and externally triggered movements with their left hand. By contrast, when patients used their right hand, levodopa led to differences in cerebellar activity only. As our patients were affected more severely on their left side, we propose that levodopa may help provide additional dopaminergic input, improving movements for the more severely affected side. These results suggest that the impact of reduced dopamine in the cortico-striatal system and the action of levodopa is not symmetrical.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25369523</PMID><DateCreated><Year>2014</Year><Month>11</Month><Day>05</Day></DateCreated><DateCompleted><Year>2015</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>11</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Asymmetrical effect of levodopa on the neural activity of motor regions in PD.</ArticleTitle><Pagination><MedlinePgn>e111600</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0111600</ELocationID><Abstract><AbstractText>Parkinson's disease (PD) is a neurodegenerative illness often characterized by asymmetrical symptoms. However, the reason for this asymmetry and the cerebral correlates underlying symptom asymmetry are still not well understood. Furthermore, the effects of levodopa on the cerebral correlates of disease asymmetry have not been investigated. In this study, right-handed PD patients performed self-initiated, externally triggered and repetitive control finger movements with both their right and left hands during functional magnetic resonance imaging (fMRI) to investigate asymmetrical effects of levodopa on the hemodynamic correlates of finger movements. Patients completed two experimental sessions OFF and ON medication after a minimum of 12 hours medication withdrawal. We compared the effect of levodopa on the neural activation patterns underlying the execution of both the more affected and less affected hand for self-initiated and externally triggered movements. Our results show that levodopa led to larger differences in cerebral activity for movements of the more affected, left side: there were significant differences in activity after levodopa administration in regions of the motor cortico-striatal network when patients performed self-initiated and externally triggered movements with their left hand. By contrast, when patients used their right hand, levodopa led to differences in cerebellar activity only. As our patients were affected more severely on their left side, we propose that levodopa may help provide additional dopaminergic input, improving movements for the more severely affected side. These results suggest that the impact of reduced dopamine in the cortico-striatal system and the action of levodopa is not symmetrical.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martinu</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagano-Saito</LastName><ForeName>Atsuko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fogel</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada; Brain & Mind Institute, Department of Psychology, Western University, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monchi</LastName><ForeName>Oury</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada; Department of Radiology, Université de Montréal, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOP-81114</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Brain. 2003 Feb;126(Pt 2):451-61</RefSource><PMID Version="1">12538411</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurosci. 2012 Feb;35(4):572-83</RefSource><PMID Version="1">22304628</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2003 Dec;126(Pt 12):2648-55</RefSource><PMID Version="1">12937076</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurophysiol. 2004 Apr;91(4):1690-8</RefSource><PMID Version="1">14645385</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1967 May;17(5):427-42</RefSource><PMID Version="1">6067254</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Brain Res. 1969;7(2):158-68</RefSource><PMID Version="1">5799432</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1989 Jan;52(1):72-6</RefSource><PMID Version="1">2709038</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1989 Nov;39(11 Suppl 2):4-6</RefSource><PMID Version="1">2573862</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4</RefSource><PMID Version="1">1564476</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1992 Dec;32(6):749-57</RefSource><PMID Version="1">1471865</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Brain Res. 1992;91(3):363-84</RefSource><PMID Version="1">1483512</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Brain Res. 1992;91(3):385-95</RefSource><PMID Version="1">1483513</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Comput Assist Tomogr. 1994 Mar-Apr;18(2):192-205</RefSource><PMID Version="1">8126267</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1994 May;57(5):562-6</RefSource><PMID Version="1">8201324</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychiatry Res. 1998 Jul 15;83(1):7-22</RefSource><PMID Version="1">9754701</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Geriatr Soc. 2005 Apr;53(4):695-9</RefSource><PMID Version="1">15817019</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2000 Jun;123 ( Pt 6):1216-28</RefSource><PMID Version="1">10825359</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2001 Mar;124(Pt 3):558-70</RefSource><PMID Version="1">11222456</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2001 Dec 11;57(11):2083-8</RefSource><PMID Version="1">11739830</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2002 Jan;15(1):1-15</RefSource><PMID Version="1">11771969</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2002 Jul 23;59(2):220-6</RefSource><PMID Version="1">12136061</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2005 Jun 14;64(11):1925-30</RefSource><PMID Version="1">15955945</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2005 Oct;128(Pt 10):2250-9</RefSource><PMID Version="1">15958505</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2005 Dec;28(4):1056-62</RefSource><PMID Version="1">16125975</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacopsychiatry. 2006 Feb;39 Suppl 1:S68-71</RefSource><PMID Version="1">16508900</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2006 Sep;5(9):796-802</RefSource><PMID Version="1">16914408</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2008 Dec;14(8):633-5</RefSource><PMID Version="1">18346926</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurosci. 2009 Mar;29(6):1277-86</RefSource><PMID Version="1">19302163</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurol. 2009 Apr;16(4):475-81</RefSource><PMID Version="1">19187264</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2009 Sep;15(8):558-63</RefSource><PMID Version="1">19467909</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Brain Mapp. 2010 Jan;31(1):88-97</RefSource><PMID Version="1">19585587</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2011 Jan;17(1):58-60</RefSource><PMID Version="1">20974546</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychol Rev. 2011 Dec;21(4):405-24</RefSource><PMID Version="1">21956794</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>IEEE Trans Med Imaging. 2002 Oct;21(10):1280-91</RefSource><PMID Version="1">12585710</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006225" MajorTopicYN="N">Hand</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009068" MajorTopicYN="N">Movement</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4219727</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>05</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>09</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25369523</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0111600</ArticleId><ArticleId IdType="pii">PONE-D-14-18118</ArticleId><ArticleId IdType="pmc">PMC4219727</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Martinu, Kristina" sort="Martinu, Kristina" uniqKey="Martinu K" first="Kristina" last="Martinu">Kristina Martinu</name></noRegion><name sortKey="Fogel, Stuart" sort="Fogel, Stuart" uniqKey="Fogel S" first="Stuart" last="Fogel">Stuart Fogel</name><name sortKey="Monchi, Oury" sort="Monchi, Oury" uniqKey="Monchi O" first="Oury" last="Monchi">Oury Monchi</name><name sortKey="Nagano Saito, Atsuko" sort="Nagano Saito, Atsuko" uniqKey="Nagano Saito A" first="Atsuko" last="Nagano-Saito">Atsuko Nagano-Saito</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000789 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000789 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25369523
|texte= Asymmetrical effect of levodopa on the neural activity of motor regions in PD.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25369523" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |